Skip to content

Total debt at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$180.9M+69.8%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$834K-27.7%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$445.39M+32.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$328K-59.1%
Janux Therapeutics logo
Janux TherapeuticsJANX
$21.57M-4.6%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $456.93K.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s total debt?
TuHURA Biosciences, Inc. (HURA) reported total debt of $456.93K in Q1 2026.
How has TuHURA Biosciences, Inc.'s total debt changed year-over-year?
TuHURA Biosciences, Inc.'s total debt increased by 177.6% year-over-year, from $164.59K to $456.93K.
What is the long-term trend for TuHURA Biosciences, Inc.'s total debt?
Over 2 years (2023 to 2025), TuHURA Biosciences, Inc.'s total debt has grown at a 391.4% compound annual growth rate (CAGR), from $20.82K to $502.67K.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.